Poster blogged on behalf of Catalent
Title: Site Specific ADC Generation Using SMARTagTM Technology
Speaker: Dr. David Rabuka, CSO Redwood Bioscience
Dr. David Rabuka from Redwood Bioscience, the poster presentation will discuss the development of a novel technology platform that enables precise, programmable, site- specific chemical protein modification. Leveraging the target sequence of Formylglycine Generating Enzyme, via the SMARTagâ¢ Technology, homogenous enhanced biotherapeutics can be engineered, including ADCs. The presentation will discuss how the novel conjugation chemistry results in ADCs having enhanced stability while maintaining the potency of the cytotoxic payload. Additionally, the poster will highlight data demonstrating SMARTagTM ADC efficacy and safety in preclinical tumor models and PK studies.
Catalent Profile: As your strategic partner for biologic drug development success, Catalent Biologics creates smart, tailored solutions with our superior GPEx cell line engineering and SMARTag TM ADC Technologies, clinical manufacturing, and integrated services through fill-finish to help you get better products to clinic, faster.
To find out more about Site Specific ADC Generation Using SMARTagTM Technology, take a look at this poster as provided by Catalent >
Catalent are sponsoring the European Antibody Congress this year. Book your place now and visit them at booth #17